Drospirenone, a New Progestogen, for Postmenopausal Women with Hypertension

  title={Drospirenone, a New Progestogen, for Postmenopausal Women with Hypertension},
  author={Madhavi Mallareddy and Vladimir Hanes and William B. White},
  journal={Drugs \& Aging},
The prevalence of hypertension increases in women after the menopause. Associated with the rise in postmenopausal blood pressure (BP) are increased salt sensitivity and imbalance between the renin-angiotensin-aldosterone system and nitric oxide pathways that lead to sodium and water retention. Drospirenone is the first synthetic progestogen with antialdosterone activity similar to natural progesterone. Drospirenone counteracts the salt- and water-retaining effects of estrogen and causes… 

Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review

All studies agree that the combination of estradiol 1 mg plus drospirenone 2 mg is a good choice for postmenopausal women with vasomotor symptoms.

The “newer” progestogens and postmenopausal hormone therapy (HRT)

  • A. Schindler
  • Medicine, Biology
    The Journal of Steroid Biochemistry and Molecular Biology
  • 2014

Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies.

  • A. BoldoW. White
  • Medicine
    Endocrinology and metabolism clinics of North America
  • 2011

Mineralocorticoid receptor haplotype moderates the effects of oral contraceptives and menstrual cycle on emotional information processing

In MR-haplotype 1/3 carriers, ML women gambled more than EF women when their risk to lose was relatively small and showed more risky decision-making, which may support previous observations in female carriers of MR- haplotype 2 in a naturalistic cohort study.

Ricadute sull'appaRato caRdio-vascolaRe delle diffeRenti foRme di teRapia oRmonale sostitutiva nelle donne in menopausa

When women are older and/or already affected by atherogenic burden, ischemic coronary events and stroke are increased by estrogen plus progestin therapy, especially in the first year of treatment (“early harm”) due to adverse hepatocellular effects of oral estrogen on coagulant cascade and inflammation as a consequence of the first liver passage.

Biofunctional roles of estrogen in coronavirus disease 2019: Beyond a steroid hormone

Findings suggest that estrogen plays a protective role in the pathophysiology of COVID-19, and that increased expression of specific types of estrogen appears to protect patients from SARS-CoV-2 infection, thereby, reducing mortality.

Rational drug repositioning by medical genetics

The 135 matches notably included the most illustrative examples of identical matches derived from GWAS, such as that 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) can lower blood cholesterol levels (hypercholesterolemia) and strongly suggest that the rationality principle can be applied to find new uses for old drugs and predict drug side effects based on mismatch information.



Effects of a New Hormone Therapy, Drospirenone and 17-&bgr;-Estradiol, in Postmenopausal Women With Hypertension

Data show that DRSP combined with E2 significantly reduces BP in postmenopausal women with hypertension and did not induce significant increases in serum potassium, which may lead to a new benefit for this novel hormone therapy in postwomen's hypertension.

Antihypertensive Effects of Drospirenone With 17&bgr;-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension

Combination therapy with DRSP/E2 significantly lowered both clinic and 24-hour systolic BP in postmenopausal women with stage 1 systolics hypertension, which may lead to benefit for cardiovascular risk reduction in this population of women.

Medroxyprogesterone Acetate But Not Drospirenone Ablates the Protective Function of 17β-Estradiol in Aldosterone Salt-Treated Rats

The hypothesis of complex interactions among estrogen, progesterone, glucocorticoid, androgen, and mineralocortICoid receptor signaling in cardiovascular injury and inflammation is supported.

Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide

DRSP/E2 substantially lowers systolic and diastolic blood pressure when added to existing antihypertensive therapy with HCTZ in hypertensive postmenopausal women and has a potassium-sparing effect that counteracts HCTz-induced potassium loss.

Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.

To the authors' knowledge, this is the first report on a combined OC that leads to a small decrease in body weight and blood pressure and may be especially beneficial for women susceptible for a gain in weight and a rise in blood pressure.